September 2007
Worldwide Biotech;Sep2007, Vol. 19 Issue 9, p8
Trade Publication
The article reports on the initiation of the phase II clinical trial of BL-1020 antipsychotic agent by drug development company BioLinex Ltd. The clinical trial will focus on the maximal tolerated dose determination of BL-1020 on schizophrenic patients. The trial will be conducted in several centers in Israel and Romania. Accordingly, based on the initial trial, BL-1020 has the potential to be clinically efficacious with minimal therapy-limiting side effects.


Related Articles

  • Examining the Rationale for Antipsychotic Polypharmacy. Fiorello, Steven J. // Behavioral Health Management;Nov/Dec2003, Vol. 23 Issue 6, pS2 

    Examines the rationale on the use of combination antipsychotic therapy or polypharmacy for the treatment of schizophrenia. Definition of such therapy; History of the use of antipsychotic medications; Findings of several surveys on the prescription of polypharmacy to patients in hospitals and...

  • Maintenance Antipsychotic Therapy Subjective: Quality of Life in Patients with Schizophrenia. Neznanov, Nikolay Grigorievich; Ivanov, Mikhail Vladimirovich; Maslovsky, Sergei Yulianovich // International Journal of Mental Health;Dec2005, Vol. 34 Issue 4, p11 

    The article studies the application of antipsychotic therapy on patients with Schizophrenia. The therapy prescribes an indefinite period of drug intake or a determined intake duration in accordance with the accepted standards that presuppose the application of the therapy during a 2-year period...

  • Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia. Sebastian, C. Simon; Glazer, William; Buckley, Peter F. // Current Medicinal Chemistry;Feb2004, Vol. 11 Issue 3, p329 

    Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long...

  • Newer Antipsychotic Drugs Appear to Stem Violent Behavior.  // Ascribe Newswire: Medicine;4/20/2004, p25 

    Researchers led by Jeffrey Swanson, at Duke University Medical Center have found that a new generation of medications called atypical antipsychotics can significantly lower the risk of violent behavior in people with schizophrenia who are being treated in community-based centers. The study...

  • Newer Antipsychotic Drugs Appear to Stem Violent Behavior.  // Ascribe Newswire: Medicine;4/15/2004, p46 

    Researchers at Duke University Medical Center, Durham, have found that a new generation of medications called atypical antipsychotics can significantly lower the risk of violent behavior in people with schizophrenia who are being treated in community-based centers. The study appears in the...

  • Drugs Before Diagnosis? Williams, Daniel // Time International (South Pacific Edition);6/26/2006, Issue 25, p41 

    The article features Australian psychiatrist Patrick McGorry and his experiment trial on schizophrenia. He believes that the disorder has a pre-onset phase wherein careful intervention could prevent them from emerging. He gave his participants regular doses of risperidone, a class of drugs known...

  • Effect of Ginkgo biloba, Risperidone and Biperiden regimen in chronic schizophrenia. Nikfarjam, M.; Goodarzi, I.; Parsai, Arshad S. H.; Parvin, N.; Safdari-Dehcheshmeh, F. // Journal of Gorgan University of Medical Sciences;Summer2012, Vol. 14 Issue 2, p23 

    Background and Objective: Schizophrenia is a disorder characterized by a chronic recurrent course. Despite the availability of an ever-expanding range of typical and atypical antipsychotics, a substantial proportion of patients with schizophrenia show a partial or total lack of response to...

  • Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. Detke, Holland C.; McDonnell, David P.; Brunner, Elizabeth; Fangyi Zhao; Sorsaburu, Sebastian; Stefaniak, Victoria J.; Corya, Sara A. // BMC Psychiatry;2010, Vol. 10, p43 

    Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation...

  • Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. Resnick, Sandra G.; Rosenheck, Robert A.; Canive, Jose M.; De Souza, Cyril; Stroup, T. Scott; McEvoy, Joseph; Davis, Sonia; Keefe, Richard S. E.; Swartz, Marvin; Lieberman, Jeffrey // Journal of Behavioral Health Services & Research;Apr2008, Vol. 35 Issue 2, p215 

    Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics